A dose escalation, randomized, placebo-controlled study designed to investigate the safety, feasibility and initial efficacy of local injections of plasminogen formulation for the treatment of chronic tympanic membrane perforation.
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2017
At a glance
- Drugs Plasminogen (Primary)
- Indications Wounds
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2017 New trial record
- 01 Nov 2017 According to a ProMetic Life Sciences media release, company has received clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation.